Secukinumab-induced pompholyx in a psoriasis patient
- Author(s): Eichhoff, Gerhard
- et al.
Published Web Locationhttps://doi.org/10.5070/D3264048363
With a prevalence of up to 20%, eczematous lesions are the most common skin adverse events of tumor necrosis factor alpha inhibitors. Eczematous lesions triggered by more modern biologics such as the IL17A antagonist secukinumab have been rarely reported. Herein, a case of secukinumab-induced pompholyx in a psoriasis patient is presented.